# GOLGA6L1

## Overview
GOLGA6L1 is a gene that encodes the protein golgin A6 family like 1, which is part of the golgin family of coiled-coil proteins associated with the Golgi apparatus. This protein plays a critical role in maintaining the structural integrity of the Golgi apparatus, an essential organelle involved in the modification, sorting, and packaging of proteins and lipids within the cell. Golgin A6 family like 1 is particularly involved in vesicle tethering, facilitating the transport of vesicles between the endoplasmic reticulum and the Golgi, as well as between Golgi cisternae, which is crucial for proper protein trafficking and cellular organization. The gene has been implicated in various diseases, including certain cancers, where its mutations and expression changes may influence disease pathogenesis and drug resistance (Li2023Wholeexome; Jing2020New). Further research is needed to fully understand the clinical significance of GOLGA6L1 and its potential as a therapeutic target.

## Function
GOLGA6L1 is a member of the golgin family, a group of coiled-coil proteins associated with the Golgi apparatus. These proteins are crucial for maintaining the structure of the Golgi apparatus, a central organelle involved in modifying, sorting, and packaging proteins and lipids for secretion or use within the cell. GOLGA6L1 is implicated in facilitating vesicle tethering, a process essential for the transport of vesicles between the endoplasmic reticulum and the Golgi, as well as between Golgi cisternae. This function is vital for ensuring proper protein trafficking, which is necessary for cellular organization and function.

The role of GOLGA6L1 in Golgi dynamics suggests it may influence intracellular transport processes, impacting how cells organize their internal components and respond to various physiological demands. By contributing to the maintenance of Golgi structure, GOLGA6L1 helps ensure that proteins are correctly processed and delivered to their intended destinations, which is critical for the proper functioning of cells and, by extension, the organism as a whole. The activity of GOLGA6L1 within the Golgi apparatus underscores its importance in cellular homeostasis and the broader context of cellular and organismal health.

## Clinical Significance
GOLGA6L1 has been implicated in various diseases and conditions through mutations and alterations in its expression. In the context of rectal neuroendocrine tumors (R-NETs), GOLGA6L1 is noted for its amplification, suggesting a potential role in the pathogenesis of these tumors, although specific clinical implications remain to be fully elucidated (Li2023Wholeexome). In non-serous ovarian cancers, GOLGA6L1 was identified among genes with notable q-values, indicating its potential involvement in the mutational landscape of these cancers, though its exact clinical significance is not detailed (Teer2017Mutational).

In colorectal cancer, particularly in cetuximab-resistant cases, GOLGA6L1 is frequently mutated, with mutations present in 60% of resistant patients. These mutations include missense, nonsense, in-frame insertions, and deletions, highlighting its possible role in drug resistance mechanisms (Jing2020New). In liver inflammation, GOLGA6L1 shows significant differential expression, although the clinical significance of this finding is not specified (Gerhard2018Transcriptomic). Despite these associations, the precise clinical implications of GOLGA6L1 mutations and expression changes require further investigation to establish their roles in disease pathogenesis and potential therapeutic targets.


## References


[1. (Teer2017Mutational) Jamie K. Teer, Sean Yoder, Anxhela Gjyshi, Santo V. Nicosia, Chaomei Zhang, and Alvaro N. A. Monteiro. Mutational heterogeneity in non-serous ovarian cancers. Scientific Reports, August 2017. URL: http://dx.doi.org/10.1038/s41598-017-10432-9, doi:10.1038/s41598-017-10432-9. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-10432-9)

[2. (Gerhard2018Transcriptomic) Glenn S Gerhard, Christophe Legendre, Christopher D Still, Xin Chu, Anthony Petrick, and Johanna K DiStefano. Transcriptomic profiling of obesity-related nonalcoholic steatohepatitis reveals a core set of fibrosis-specific genes. Journal of the Endocrine Society, 2(7):710–726, June 2018. URL: http://dx.doi.org/10.1210/js.2018-00122, doi:10.1210/js.2018-00122. This article has 60 citations and is from a peer-reviewed journal.](https://doi.org/10.1210/js.2018-00122)

[3. (Li2023Wholeexome) Yuanliang Li, Yiying Guo, Zixuan Cheng, Chao Tian, Yingying Chen, Ruao Chen, Fuhuan Yu, Yanfen Shi, Fei Su, Shuhua Zhao, Zhizheng Wang, Jie Luo, and Huangying Tan. Whole-exome sequencing of rectal neuroendocrine tumors. Endocrine-Related Cancer, January 2023. URL: http://dx.doi.org/10.1530/erc-22-0257, doi:10.1530/erc-22-0257. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1530/erc-22-0257)

[4. (Jing2020New) Changwen Jing, Ting Wang, Rong Ma, Haixia Cao, Zhuo Wang, Siwen Liu, Dan Chen, Junying Zhang, Yang Wu, Yuan Zhang, Jianzhong Wu, and Jifeng Feng. New genetic variations discovered in kras wild‐type cetuximab resistant chinese colorectal cancer patients. Molecular Carcinogenesis, 59(5):478–491, March 2020. URL: http://dx.doi.org/10.1002/mc.23172, doi:10.1002/mc.23172. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/mc.23172)